OTC Markets OTCPK - Delayed Quote USD

Next Science Limited (NXSCF)

Compare
0.0500
0.0000
(0.00%)
At close: April 8 at 4:00:00 PM EDT
Loading Chart for NXSCF
  • Previous Close 0.0936
  • Open 0.0936
  • Bid 0.0500 x --
  • Ask 0.0803 x --
  • Day's Range 0.0936 - 0.0936
  • 52 Week Range 0.0320 - 0.2680
  • Volume 12,000
  • Avg. Volume 1,468
  • Market Cap (intraday) 19.272M
  • Beta (5Y Monthly) 1.50
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0400
  • Earnings Date Feb 27, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.

www.nextscience.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NXSCF

View More

Performance Overview: NXSCF

Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

NXSCF
28.57%
S&P/ASX 200 [XJO] (^AXJO)
9.61%

1-Year Return

NXSCF
79.42%
S&P/ASX 200 [XJO] (^AXJO)
5.74%

3-Year Return

NXSCF
92.46%
S&P/ASX 200 [XJO] (^AXJO)
1.38%

5-Year Return

NXSCF
94.52%
S&P/ASX 200 [XJO] (^AXJO)
36.90%

Compare To: NXSCF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NXSCF

View More

Valuation Measures

Annual
As of 4/8/2025
  • Market Cap

    19.24M

  • Enterprise Value

    20.06M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.64

  • Price/Book (mrq)

    4.24

  • Enterprise Value/Revenue

    0.88

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -46.40%

  • Return on Assets (ttm)

    -47.12%

  • Return on Equity (ttm)

    -130.18%

  • Revenue (ttm)

    22.82M

  • Net Income Avi to Common (ttm)

    -10.59M

  • Diluted EPS (ttm)

    -0.0400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.67M

  • Total Debt/Equity (mrq)

    72.42%

  • Levered Free Cash Flow (ttm)

    -5.09M

Research Analysis: NXSCF

View More

Company Insights: NXSCF

Research Reports: NXSCF

View More

People Also Watch